Atlas Trials

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Clinical trial NCT03085810 · TERMINATED

Trial details

NCT number
NCT03085810
Sponsor
Hoffmann-La Roche
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Multiple Sclerosis, Relapsing-Remitting
Start date
2017-03-24
Primary completion
2023-04-27
Enrollment
1225

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.